Burning Rock Biotech (NASDAQ:BNR) Upgraded by Wall Street Zen to Buy Rating

Burning Rock Biotech (NASDAQ:BNR) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Burning Rock Biotech in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Burning Rock Biotech Stock Performance

NASDAQ BNR opened at $32.01 on Friday. The company’s 50 day simple moving average is $19.64 and its two-hundred day simple moving average is $12.08. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.14 and a quick ratio of 2.91. Burning Rock Biotech has a 1 year low of $2.18 and a 1 year high of $34.79. The stock has a market capitalization of $344.43 million, a PE ratio of -19.28 and a beta of 1.25.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Burning Rock Biotech in the third quarter valued at about $26,000. Prospera Financial Services Inc purchased a new position in Burning Rock Biotech in the 3rd quarter worth approximately $214,000. Finally, Crcm LP boosted its stake in Burning Rock Biotech by 13.8% in the 3rd quarter. Crcm LP now owns 221,575 shares of the company’s stock worth $1,917,000 after purchasing an additional 26,809 shares during the period. Institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Company Profile

Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients.

Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities.